A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma

Sponsor

Helix BioPharma Corporation (Industry)

Overall Status

Terminated

CT.gov ID

NCT03891173

Collaborator

KCR S.A. (Other)

Enrollment

Locations

Arms

Actual Duration (Months)

2.3

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study will determine the highest dose of L-DOS47 that can be given in combination with vinorelbine/cisplatin, evaluate safety and tolerability of L-DOS47 when given in combination with vinorelbine/cisplatin, and assess how effective this combination is in treating patients with lung adenocarcinoma compared to patients who are given vinorelbine/cisplatin alone.

Condition or Disease	Intervention/Treatment	Phase
Lung Adenocarcinoma	Drug: L-DOS47 Drug: Cisplatin Drug: Vinorelbine	Phase 2

Detailed Description

The study is divided into two parts. In part I, the maximum tolerated dose of L-DOS47, when given in combination with vinorelbine/cisplatin, will be determined. Cohorts of 3 patients will be recruited into three dosing cohorts (6, 9 and 12 µg/kg). All patients at a given dose level must complete the first treatment cycle (3 week period) before escalation in subsequent patients can proceed. The decision for escalation to the next dose level will be made after the safety data have been reviewed by the Trial Steering Committee (TSC). If a patient in any cohort experiences a dose limiting toxicity, an additional 3 patients will be enrolled, for a maximum of up to 18 patients in this initial dose escalation part of the study.

In part II, after the maximum tolerated dose of L-DOS47 in combination with vinorelbine/cisplatin has been determined, a further 118 patients will be randomized (1:1) to receive L-DOS47 in combination with vinorelbine/cisplatin, or vinorelbine/cisplatin alone. Efficacy will be assessed by time to progression (time from first day of study drug administration to documented disease progression), response rate (proportion of patients with a best overall response of complete response and partial response using the Response Evaluation Criteria in Solid Tumours [RECIST] version 1.1 criteria), and overall survival (time from first day of study drug administration to death due to any cause). Monitoring will include radiological evaluations every second cycle. Safety and tolerability of L-DOS47 in combination will also continue to be evaluated.

For all patients, treatment will continue either until the patient experiences disease progression, unacceptable toxicity, the patient withdraws consent or has completed four treatment cycles.

Study Design

Study Type:

Interventional

Actual Enrollment :

9 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Part I includes a brief initial dose escalation phase, followed by Part II, which includes a randomized treatment phase.Part I includes a brief initial dose escalation phase, followed by Part II, which includes a randomized treatment phase.

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase II, Open-Label, Randomized Study Immunoconjugate L-DOS47 in Combination With Vinorelbine/Cisplatin Versus Vinorelbine/Cisplatin Alone in Patients With Lung Adenocarcinoma

Actual Study Start Date :

Feb 19, 2019

Actual Primary Completion Date :

May 22, 2020

Actual Study Completion Date :

May 22, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: L-DOS47 in combination with cisplatin + vinorelbine L-DOS47 (6/9/12 µg/kg) is administered by iv on Day 1 and 8 of each 21-day treatment cycle, in combination with iv administration of standard cisplatin (80 mg/m2) on Day 2 + vinorelbine (30 mg/m2) on Day 2 and 9.	Drug: L-DOS47 L-DOS47 lyophilized powder reconstituted and diluted for iv injection Drug: Cisplatin Cisplatin concentrate for solution for iv infusion Drug: Vinorelbine Vinorelbine concentrate for solution for iv infusion Other Names: vinorelbine tartrate
Active Comparator: Cisplatin + vinorelbine alone Administration by iv of standard Cisplatin (80 mg/m2) on Day 1 + vinorelbine (30 mg/m2) on Day 1 and 8 of each 21-day treatment cycle.	Drug: Cisplatin Cisplatin concentrate for solution for iv infusion Drug: Vinorelbine Vinorelbine concentrate for solution for iv infusion Other Names: vinorelbine tartrate

Arm

Intervention/Treatment

Experimental: L-DOS47 in combination with cisplatin + vinorelbine

L-DOS47 (6/9/12 µg/kg) is administered by iv on Day 1 and 8 of each 21-day treatment cycle, in combination with iv administration of standard cisplatin (80 mg/m2) on Day 2 + vinorelbine (30 mg/m2) on Day 2 and 9.

Drug: L-DOS47

L-DOS47 lyophilized powder reconstituted and diluted for iv injection

Drug: Cisplatin

Cisplatin concentrate for solution for iv infusion

Drug: Vinorelbine

Vinorelbine concentrate for solution for iv infusion

Other Names:

vinorelbine tartrate

Active Comparator: Cisplatin + vinorelbine alone

Administration by iv of standard Cisplatin (80 mg/m2) on Day 1 + vinorelbine (30 mg/m2) on Day 1 and 8 of each 21-day treatment cycle.

Drug: Cisplatin

Cisplatin concentrate for solution for iv infusion

Drug: Vinorelbine

Vinorelbine concentrate for solution for iv infusion

Other Names:

vinorelbine tartrate

Outcome Measures

Primary Outcome Measures

Time to disease progression [Up to 12 weeks]
Time from first day of study drug administration to documentation of disease progression (including death due to progression)

Secondary Outcome Measures

Objective response rate as measured using RECIST v. 1.1 [Up to 12 weeks]
Proportion of patients with a best overall response of complete response and partial response
Overall survival [Up to 12 weeks]
Time to death as defined as time from first day of study drug administration to death to to any cause
Safety and tolerability of L-DOS47 in combination with vinorelbine/cisplatin: Frequency of treatment emergence adverse events in patients [Up to 12 weeks]
Frequency of treatment emergent adverse events in patients

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Male or female aged ≥ 18 years old
Histologically confirmed lung adenocarcinoma, classified as:

Chemotherapy-naive patients with metastatic lung adenocarcinoma for whom vinorelbine/cisplatin would be appropriate therapy;
metastatic recurrent lung adenocarcinoma following prior surgery, radiation and/or adjuvant chemotherapy at least 6 months ago, for whom vinorelbine/cisplatin would be appropriate therapy;
Staging assessed according to Tumor Node Metastases (TNM), 8th edition and based on computed tomography (CT) scan;
Grade 1 - 4 adenocarcinoma

No prior adjuvant chemotherapy within 6 months of the first treatment day if there is recurrent disease
At least a single measurable lesion in accordance with the RECIST v1.1 criteria
Eastern Cooperative Oncology Group (ECOG) performance status: 0-1
A life expectancy of ≥ 3 months
Adequate organ function as determined by the following criteria:

Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L
Platelet count ≥ 100 × 10^9/L
Haemoglobin (HGB) ≥ 9 g/dL
Creatinine clearance ≥ 60 mL/min calculated using the Cockcroft-Gault Formula and serum creatinine ≤ 1.5 × the upper limit of normal (ULN)
Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) ≤ 3 × ULN or < 5 × ULN if liver abnormalities are due to underlying malignancy
Total bilirubin ≤ 1.5 × ULN Note: Blood transfusions administered for the sole purpose of meeting the study inclusion criteria between the time informed consent is signed and first dose of L-DOS47 is administered are not allowed.

Able to understand the information provided to them and to give written informed consent before any study activities are conducted
Willing and able to comply with scheduled visits, treatment plans, laboratory tests and other study procedures
Not pregnant and do not plan to become pregnant during the study. Females of childbearing potential must provide a negative pregnancy test within the Screening period (Day 21 to 0) and agree to use adequate non-hormonal contraception (which includes but is not limited to double barrier or sexual abstinence) during the study and for a period of 90 days following the last dose of study treatment. Male patients and their female partners of child-bearing potential must agree to each use an approved form of contraception during the study and for a period of 90 days following the last dose of study treatment.

Exclusion Criteria:

Pregnant or nursing mother
Prior history of other malignancies with the exception of non melanoma skin cancer
Patients with a known positive Epidermal Growth Factor Receptor (EGFR) mutation or whose tumour harbour an anaplastic lymphoma kinase (ALK) translocation
Active central nervous system metastasis and/or leptomeningeal disease (known or suspected); Patients with asymptomatic brain metastases are eligible if they had local therapy more than 1 month before enrolment
Evidence of active infection
Received treatment in another clinical study within the 30 days before commencing study drug and have not recovered from side effects of a study drug, except for alopecia
A serious uncontrolled medical condition
Known positive human immunodeficiency virus (HIV), known hepatitis B surface antigen, or hepatitis C positive
Sustained QT interval corrected for heart rate (QTc) with Fridericia's correction > 450 msec at Screening, or a history of additional risk factors for Torsades de pointes (e.g., heart failure, hypokalaemia, family history of long QT syndrome)
Pre-existing peripheral neuropathy Grade ≥ 1 CTCAE
Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent or compliance with the requirements of the protocol
Receiving chemotherapy during the 30 days before study treatment start; are receiving radiotherapy, targeted therapy, hormonal therapy, immunotherapy, major surgery or other study drugs during the 4 weeks before study treatment start, or have not recovered from all treatment related toxicities to Grade ≤ 1, except for alopecia. (Radiotherapy is allowed for the symptomatic treatment of bone metastases.)
Taking systemic steroids (other than inhalers or topical steroids) or other medication to suppress the immune system
Participating (or planning to participate) in any other clinical trial during this study

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	Europejskie Centrum Zdrowia Otwock	Otwock	Poland	05-400
2	Dnipropetrovsk City Multi-field Clinical Hospital #4	Dnipro	Ukraine	49102
3	Sumy Regional Clinical Oncological Centre	Sumy	Ukraine	40005
4	Vinnytsya Regional Clinical Oncological Centre	Vinnytsia	Ukraine	21029